Efficacy and pharmacokinetics of gallopamil in patients with coronary artery disease

Nicola Ferrara, Giancarlo Longobardi, Nunzio Guerra, Antonio Nicolino, Domenico Acanfora, Giuseppe Furgi, Luigi Odierna, Renato Rosiello, Franco Rengo

Research output: Contribution to journalArticle

Abstract

We prospectively studied 10 patients with stable exertional ischaemia, selected from a larger group of patients referred for suspected coronary artery disease or to detect residual ischaemia after myocardial infarction, to evaluate pharmacokinetic changes during chronic treatment with gallopamil and its correlation with clinical efficacy in patients with coronary artery disease. Our study consisted of a 1-week run-in single-blind placebo treatment and a 4-week single-blind gallopamil treatment. At the end of the run-in period patients underwent two different exercise tests, the first 2 hours and the second 7 hours after placebo administration. During active treatment all patients underwent two different exercise tests, the first 2 hours and the second 7 hours after gallopamil (50 mg) administration on the 1st and 28th days of gallopamil therapy, On the same days in eight of the patients we evaluated gallopamil pharmacokinetic changes. Our data revealed a rapid increase of unchanged gallopamil and its metabolite (norgallopamil) in the plasma, and a peak concentration of these substances about 2 hour after oral administration on both the 1st and 28th day of observation. Moreover, our results demonstrated an increase between the first and 28th day of treatment in peak concentration of unchanged gallopamil in the plasma, and of AUC 0-∞ and AUC o-c values during chronic treatment with gallopamil. Our clinical data showed an improvement in exercise results during gallopamil therapy related to increased concentration of the drug.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalPharmacological Research
Volume34
Issue number1-2
DOIs
Publication statusPublished - Jul 1996

Keywords

  • Coronary artery disease
  • Gallopamil

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Efficacy and pharmacokinetics of gallopamil in patients with coronary artery disease'. Together they form a unique fingerprint.

Cite this